Top 10 Most Profitable Biotech Stocks: IMMU, KERX, TECH, GILD, SVA, CRME, CPHI, AMGN, CELG, CYTK (Jun 15, 2010)

Posted: 15 Jun 2010 08:29 AM PDT

Below are the top 10 most profitable Biotechnology stocks for the last 12 months. Two Chinese companies (SVA, CPHI) are on the list.

Immunomedics, Inc. (NASDAQ:IMMU) is the 1st most profitable stock in this segment of the market. Its net profit margin was 58.79% for the last 12 months. Its operating profit margin was 55.97% for the same period. Keryx Biopharmaceuticals (NASDAQ:KERX) is the 2nd most profitable stock in this segment of the market. Its net profit margin was 41.62% for the last 12 months. Its operating profit margin was 38.97% for the same period. Techne Corporation (NASDAQ:TECH) is the 3rd most profitable stock in this segment of the market. Its net profit margin was 41.17% for the last 12 months. Its operating profit margin was 57.57% for the same period. Gilead Sciences, Inc. (NASDAQ:GILD) is the 4th most profitable stock in this segment of the market. Its net profit margin was 38.21% for the last 12 months. Its operating profit margin was 51.30% for the same period. Sinovac Biotech Ltd. (NASDAQ:SVA) is the 5th most profitable stock in this segment of the market. Its net profit margin was 36.12% for the last 12 months. Its operating profit margin was 48.44% for the same period.

CARDIOME PHARMA CORP (NASDAQ:CRME) is the 6th most profitable stock in this segment of the market. Its net profit margin was 34.35% for the last 12 months. Its operating profit margin was 41.63% for the same period. China Pharma Holdings, Inc. (AMEX:CPHI) is the 7th most profitable stock in this segment of the market. Its net profit margin was 32.68% for the last 12 months. Its operating profit margin was 36.64% for the same period. Amgen, Inc. (NASDAQ:AMGN) is the 8th most profitable stock in this segment of the market. Its net profit margin was 31.84% for the last 12 months. Its operating profit margin was 37.96% for the same period. Celgene Corporation (NASDAQ:CELG) is the 9th most profitable stock in this segment of the market. Its net profit margin was 29.50% for the last 12 months. Its operating profit margin was 33.01% for the same period. Cytokinetics, Inc. (NASDAQ:CYTK) is the 10th most profitable stock in this segment of the market. Its net profit margin was 29.13% for the last 12 months. Its operating profit margin was 31.18% for the same period. 

• Technical Analysis Alerts Free Technical Analysis Newsletter Alerts On Penny Stocks About To Run

• Peak Crude Oil Prices Thinking about investing in Crude? Then this free report is a must.

• Cheap Stock Motels Find Low Hotel Rates! Save Time & Compare Before You Book Online.

• Warren Buffett System Download the step-by-step guide to investing just like Warren Buffett.